{"changeSha256":"1bb11a62aa9f39be1054a37ca6459f45f996bdb3179dae20c9d9d1118514fa4e","changedAt":"2026-11-14","changedFields":[{"after":"FDA-approved as Ozempic, Rybelsus and Wegovy","before":"U.S. label record","field":"Status"},{"after":"A GLP-1 receptor agonist approved by FDA as Ozempic, Rybelsus and Wegovy. Its approved uses rest on large randomized trials described in the label.","before":"A GLP-1 receptor agonist. This profile cites a Wegovy label and an FDA notice.","field":"Profile summary"},{"after":"The Wegovy label covers weight reduction, cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and MASH under accelerated approval, and carries a boxed warning about thyroid C-cell tumors in rodents. FDA says compounded and other unapproved semaglutide products are not FDA-approved.","before":"The cited DailyMed label identifies Semaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.","field":"Evidence note"},{"after":"dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026, fda-semaglutide-identity, fda-drugs-nda209637-2017-12-05-0b9e82eeabee, fda-drugs-nda213051-2019-09-20-2bce5be175e9, fda-drugs-nda215256-2021-06-04-bead2c63a813, fda-drugs-nda218316-2025-12-22-e39b0518156a, fda-glp1-label-warning-request-2026, fda-glp1-bulks-proposal-2026, fda-unapproved-glp1-concerns-2026-r2","before":"dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026, fda-semaglutide-identity","field":"Cited source records"},{"after":"U.S. National Library of Medicine [sources: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19]; U.S. Food and Drug Administration [sources: fda-drugs-nda209637-2017-12-05-0b9e82eeabee, fda-unapproved-glp1-concerns-2026-r2]","before":"U.S. National Library of Medicine [sources: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19]","field":"Named organizations"},{"after":"name: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; aliases: fda-semaglutide-identity; category: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; status: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-drugs-nda209637-2017-12-05-0b9e82eeabee, fda-drugs-nda213051-2019-09-20-2bce5be175e9, fda-drugs-nda215256-2021-06-04-bead2c63a813; summary: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-drugs-nda209637-2017-12-05-0b9e82eeabee, fda-drugs-nda213051-2019-09-20-2bce5be175e9, fda-drugs-nda215256-2021-06-04-bead2c63a813; evidenceNote: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-unapproved-glp1-concerns-2026-r2","before":"name: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; aliases: fda-semaglutide-identity; category: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; status: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; summary: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026; evidenceNote: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/semaglutide/versions/4/","version":4},"id":"profile:semaglutide:v4","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, re-checked the Wegovy label and the Drugs@FDA approval records, and added FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026) and its April 2026 503B proposal. An August 2026 Ozempic supplement changed carton labeling only and is not reflected.","peptideSlugs":["semaglutide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/semaglutide/v3.json","sha256":"354e0739a78f14945650ff8784dd5bbc37832b1a56de10b4e6bb2e984160dd70"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/semaglutide/versions/3/","version":3},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19","name":"DailyMed · U.S. National Library of Medicine","sourceClass":"A","title":"WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30","url":"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=19","verifiedAt":"2026-07-22"},{"id":"fda-drugs-nda209637-2017-12-05-0b9e82eeabee","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA209637%22&limit=1","verifiedAt":"2026-08-14"},{"id":"fda-unapproved-glp1-concerns-2026-r2","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","verifiedAt":"2026-11-14"}],"subject":{"slug":"semaglutide","type":"profile"}}
